Membrane-disruptive peptides/peptidomimetics-based therapeutics: Promising systems to combat bacteria and cancer in the drug-resistant era
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Membrane-disruptive peptides/peptidomimetics (MDPs) are antimicrobials or anticarcinogens that present a general killing mechanism through the physical disruption of cell membranes, in contrast to conventional chemotherapeutic drugs, which act on precise targets such as DNA or specific enzymes. Owing to their rapid action, broad-spectrum activity, and mechanisms of action that potentially hinder the development of resistance, MDPs have been increasingly considered as future therapeutics in the drug-resistant era. Recently, growing experimental evidence has demonstrated that MDPs can also be utilized as adjuvants to enhance the therapeutic effects of other agents. In this review, we evaluate the literature around the broad-spectrum antimicrobial properties and anticancer activity of MDPs, and summarize the current development and mechanisms of MDPs alone or in combination with other agents. Notably, this review highlights recent advances in the design of various MDP-based drug delivery systems that can improve the therapeutic effect of MDPs, minimize side effects, and promote the co-delivery of multiple chemotherapeutics, for more efficient antimicrobial and anticancer therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21660 · Cited by 108,699
Biofilms: an emergent form of bacterial life
Flemming, H.-C., Wingender, J., Szewzyk, U., Steinberg, P., Rice, S. A., & Kjelleberg, S. (2016) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2016.94 · Cited by 5,979
Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria?
Brogden, K. A. (2005) · Nature Reviews Microbiology · doi:10.1038/nrmicro1098 · Cited by 5,829
Engineered Nanoparticles for Drug Delivery in Cancer Therapy
Sun, T., Zhang, Y. S., Pang, B., Hyun, D. C., Yang, M., & Xia, Y. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201403036 · Cited by 2,164
The immunopathology of sepsis and potential therapeutic targets
van der Poll, T., van de Veerdonk, F. L., Scicluna, B. P., & Netea, M. G. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2017.36 · Cited by 1,957
Aggarwal, P., Hall, J. B., McLeland, C. B., Dobrovolskaia, M. A., & McNeil, S. E. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.03.009 · Cited by 1,791
Measurement of gastrointestinal pH profiles in normal ambulant human subjects
Evans, D. F., Pye, G., Bramley, R., Clark, A. G., Dyson, T. J., & Hardcastle, J. D. (1988) · Gut · doi:10.1136/gut.29.8.1035 · Cited by 1,240
Rapid transport of large polymeric nanoparticles in fresh undiluted human mucus
Lai, S. K., O'Hanlon, D. E., Harrold, S., Man, S. T., Wang, Y.-Y., Cone, R., & Hanes, J. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0608611104 · Cited by 1,050
Binding of polymyxin B to the lipid A portion of bacterial lipopolysaccharides
Morrison, D. C., & Jacobs, D. M. (1976) · Immunochemistry · doi:10.1016/0019-2791(76)90181-6 · Cited by 819
Recent progress in drug delivery
Li, C., Wang, J., Wang, Y., Gao, H., Wei, G., Huang, Y., Yu, H., Gan, Y., Wang, Y., Mei, L., et al. (2019) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2019.08.003 · Cited by 818
Adapting liposomes for oral drug delivery
He, H., Lu, Y., Qi, J., Zhu, Q., Chen, Z., & Wu, W. (2019) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2018.06.005 · Cited by 663
Chen, C. Z., Beck-Tan, N. C., Dhurjati, P., van Dyk, T. K., LaRossa, R. A., & Cooper, S. L. (2000) · Biomacromolecules · doi:10.1021/bm0055495 · Cited by 443
Crossing the Blood–Brain Barrier: Recent Advances in Drug Delivery to the Brain
Patel, M. M., & Patel, B. M. (2017) · CNS Drugs · doi:10.1007/s40263-016-0405-9 · Cited by 430
Zhou, T., Hu, R., Wang, L., Qiu, Y., Zhang, G., Deng, Q., Zhang, H., Yin, P., Situ, B., Zhan, C., et al. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.201916704 · Cited by 265
AIEgens for microbial detection and antimicrobial therapy
Bai, H., He, W., Chau, J. H. C., Zheng, Z., Kwok, R. T. K., Lam, J. W. Y., & Tang, B. Z. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2020.120598 · Cited by 130
Cited by
Antimicrobial Peptides—Mechanisms of Action, Antimicrobial Effects and Clinical Applications
Talapko, J., Meštrović, T., Juzbašić, M., Tomas, M., Erić, S., Horvat Aleksijević, L., Bekić, S., Schwarz, D., Matić, S., Neuberg, M., et al. (2022) · Antibiotics · doi:10.3390/antibiotics11101417 · Cited by 281
Furukawa, N., Yang, W., Chao, A. R., Patil, A., Mirando, A. C., Pandey, N. B., & Popel, A. S. (2024) · Cell Death Discovery · doi:10.1038/s41420-024-01932-5 · Cited by 10
Furukawa, N., Yang, W., Chao, A., Patil, A., Mirando, A., Pandey, N., & Popel, A. (2023) · doi:10.21203/rs.3.rs-3335225/v1 · Cited by 10
Metadata
- Authors
- Lin, L., Chi, J., Yan, Y., Luo, R., Feng, X., Zheng, Y., Xian, D., Li, X., Quan, G., Liu, D., Wu, C., Lu, C., & Pan, X.
- Venue
- Acta Pharmaceutica Sinica B
- Publisher
- Elsevier BV
- Published
- 2021-09
- Volume
- 11
- Issue
- 9
- Pages
- 2609-2644
- ISSN
- 2211-3835 (ISSN-L)
- OpenAlex
- W3184585025
- Cited by
- 182
- References
- 15
- FWCI
- 13.00
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.